Intravenous Ferric Carboxymaltose in Ulcerative Colitis: Indications, Dosing, Safety, and Monitoring

Indications

The European Crohn’s and Colitis Organisation (ECCO) recommends ferric carboxymaltose as a first‑line intravenous iron therapy for ulcerative colitis patients who have clinically active disease, prior intolerance to oral iron, hemoglobin < 10 g/dL, or who require erythropoiesis‑stimulating agents. 1
In patients with hemoglobin < 10 g/dL, ferric carboxymaltose provides a more rapid correction of anemia than oral iron preparations. 1
When erythropoiesis‑stimulating agents are needed, intravenous ferric carboxymaltose improves the agents’ efficacy compared with oral iron. 1

Ferric carboxymaltose can be administered in single infusions of 500–1000 mg (up to 20 mg/kg body weight), simplifying treatment schedules. 1
No test dose is required before the therapeutic infusion, avoiding the anaphylaxis risk associated with iron dextran. 1

Weight‑ and hemoglobin‑based dosing scheme (simplified alternative to the Ganzoni formula):

Baseline Hemoglobin (g/dL)	Body weight < 70 kg	Body weight ≥ 70 kg
10–12 (women) / 10–13 (men)	1000 mg	1500 mg
7–10	1500 mg	2000 mg

This dosing table is derived from ECCO‑endorsed studies. 2

Initial clinical trials reported no cases of anaphylaxis with ferric carboxymaltose in inflammatory bowel disease patients. 3
The FDA label highlights hypophosphatemia as a potential adverse effect; phosphate levels should be checked before repeat dosing if the interval is ≤ 3 months. 3

The therapeutic aim is to normalize hemoglobin and replenish iron stores in ulcerative colitis patients. 2
An increase of ≥ 2 g/dL in hemoglobin within 4 weeks is considered an acceptable response. 2
Post‑treatment ferritin should be > 400 µg/L to reduce the risk of anemia recurrence for 1–5 years. [1][4]
Patients should be monitored every 3 months during the first year after iron repletion. 4
Re‑treatment is indicated when ferritin falls below 100 µg/L or hemoglobin drops below 12–13 g/dL (gender‑specific thresholds). 4

Oral iron may be used in clinically inactive ulcerative colitis. 1
It is appropriate for mild anemia (approximately 11.0–11.9 g/dL in women and 11.0–12.9 g/dL in men). 4
The maximum oral elemental iron dose should not exceed 100 mg per day. 4
However, oral iron can exacerbate intestinal inflammation, promote carcinogenesis, and alter gut microbiota, limiting its use in ulcerative colitis. 1

Oral iron preparations cause black stools because over 90% of ingested iron remains unabsorbed in the gastrointestinal tract, leading to dark discoloration of stool, as noted by the European Crohn's and Colitis Organisation 5, 6

Oral iron frequently causes gastrointestinal adverse effects including nausea, flatulence, diarrhea, and gastric erosion due to unabsorbed iron in the gut, according to the European Society for Clinical Nutrition and Metabolism 5, 6
In patients with inflammatory bowel disease, unabsorbed oral iron can generate reactive oxygen species that may exacerbate disease activity, as reported by the European Crohn's and Colitis Organisation 5, 6

Hypotension and flushing are the most frequently reported systemic effects of IV iron sucrose, as stated by the American Society of Health-System Pharmacists 7
Arthralgia/myalgias, or joint and muscle pain, are also common side effects of IV iron sucrose, according to the American College of Rheumatology 7, 8

If a patient on IV iron sucrose develops black stools, investigate for gastrointestinal bleeding rather than attributing it to the iron therapy, as recommended by the American Gastroenterological Association 5, 6
Patients with inflammatory bowel disease, hemodialysis patients, and those on antiplatelet drugs or anticoagulants are at higher risk of gastrointestinal bleeding and should be monitored closely, as advised by the International Society of Nephrology 9